# Pacritinib Citrate (Vonjo)

Source: https://ourhealthnetwork.com/drugs/pacritinib-citrate
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Pacritinib Citrate?

Pacritinib Citrate (brand name: Vonjo) is a kinase inhibitor. It is prescribed to treat primary myelofibrosis. Across the United States, 85 doctors prescribe Pacritinib to approximately 13 Medicare patients.

## Brand names

Vonjo

## Indications

Pacritinib Citrate is primarily prescribed for the treatment of primary myelofibrosis.

## Conditions treated

- [Primary Myelofibrosis](https://ourhealthnetwork.com/conditions/primary-myelofibrosis)

## Mechanism of action

Pacritinib is an oral kinase inhibitor with activity against wild type Janus associated kinase 2 (JAK2), mutant JAK2V617F, FMS-like tyrosine kinase 3 (FLT3), and interleukin 1 receptor associated kinase-1 (IRAK1) which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Pacritinib is also an inhibitor of activin A receptor,

## Drug classification

- Established Pharmacologic Class: Kinase Inhibitor [EPC]
- Mechanism of Action class: Tyrosine Kinase Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

mg twice daily were anemia, seven

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)